Lineage Cell (Israel) Probability of Future Stock Price Finishing Over 207.59
| BTX Stock | ILS 217.00 5.00 2.36% |
Lineage |
Lineage Cell Target Price Odds to finish over 207.59
The tendency of Lineage Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above S 207.59 in 90 days |
| 217.00 | 90 days | 207.59 | about 99.0 |
Based on a normal probability distribution, the odds of Lineage Cell to stay above S 207.59 in 90 days from now is about 99.0 (This Lineage Cell Therapeutics probability density function shows the probability of Lineage Stock to fall within a particular range of prices over 90 days) . Probability of Lineage Cell Therapeutics price to stay between S 207.59 and its current price of S217.0 at the end of the 90-day period is near 1 .
Assuming the 90 days trading horizon Lineage Cell Therapeutics has a beta of -1.42 suggesting as returns on its benchmark rise, returns on holding Lineage Cell Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Lineage Cell is expected to outperform its benchmark. Additionally Lineage Cell Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Lineage Cell Price Density |
| Price |
Predictive Modules for Lineage Cell
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Lineage Cell Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Lineage Cell Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Lineage Cell is not an exception. The market had few large corrections towards the Lineage Cell's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Lineage Cell Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Lineage Cell within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.44 | |
β | Beta against Dow Jones | -1.42 | |
σ | Overall volatility | 47.87 | |
Ir | Information ratio | -0.13 |
Lineage Cell Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Lineage Cell for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Lineage Cell Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Lineage Cell generated a negative expected return over the last 90 days | |
| Lineage Cell has high historical volatility and very poor performance | |
| The company reported the revenue of 4.99 M. Net Loss for the year was (45.99 M) with profit before overhead, payroll, taxes, and interest of 4.69 M. | |
| Lineage Cell Therapeutics has accumulated about 27.1 M in cash with (30.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.18. |
Lineage Cell Technical Analysis
Lineage Cell's future price can be derived by breaking down and analyzing its technical indicators over time. Lineage Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Lineage Cell Therapeutics. In general, you should focus on analyzing Lineage Stock price patterns and their correlations with different microeconomic environments and drivers.
Lineage Cell Predictive Forecast Models
Lineage Cell's time-series forecasting models is one of many Lineage Cell's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Lineage Cell's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Lineage Cell Therapeutics
Checking the ongoing alerts about Lineage Cell for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Lineage Cell Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Lineage Cell generated a negative expected return over the last 90 days | |
| Lineage Cell has high historical volatility and very poor performance | |
| The company reported the revenue of 4.99 M. Net Loss for the year was (45.99 M) with profit before overhead, payroll, taxes, and interest of 4.69 M. | |
| Lineage Cell Therapeutics has accumulated about 27.1 M in cash with (30.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.18. |
Additional Information and Resources on Investing in Lineage Stock
When determining whether Lineage Cell Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lineage Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lineage Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lineage Cell Therapeutics Stock:Check out Lineage Cell Backtesting, Lineage Cell Valuation, Lineage Cell Correlation, Lineage Cell Hype Analysis, Lineage Cell Volatility, Lineage Cell History as well as Lineage Cell Performance. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.